Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective

Abstract

The epidermal growth factor receptor (EGFR), a member of the ErbB family (EGFR, ErbB2, ErbB3 and ErbB4), plays a crucial role in regulating various cellular responses such as proliferation, differentiation, and survival. As a result, aberrant activation of EGFR, mostly mediated through different classes of genomic alterations occurring within EGFR, is closely associated with the pathogenesis of numerous human cancers including lung adenocarcinoma, glioblastoma, and colorectal cancer. Thus, specific suppression of oncogenic activity of mutant EGFR with its targeted drugs has been routinely used in the clinic as a very effective anti-cancer strategy in treating a subset of tumors driven by such oncogenic EGFR mutants. However, the clinical efficacy of EGFR-targeted therapy does not last long due to several resistance mechanisms that emerge in the patients following the drug treatment. Thus, there is an urgent need for the development of novel therapeutic tactics specifically targeting mutant EGFR with the focus on the unique biological features of various mutant EGFR. Regarding this point, our review specifically emphasizes the recent findings about distinct requirements of receptor dimerization and autophosphorylation, which are critical steps for enzymatic activation of EGFR and signaling cascades, respectively, among wildtype and mutant EGFR and further discuss their clinical significance. In addition, the molecular mechanisms regulating EGFR dimerization and enzymatic activity by a key negative feedback inhibitor Mig6 as well as the clinical use for developing potential novel drugs targeting it are described in this review. [BMB Reports 2020; 53(3): 133-141] BMB Rep. 2020; 53(3): 133-141 www.bmbreports.org Invited Mini ReviewActivation and inactivation mechanisms of wild type and mutant EGFR Jeonghee Cho BMB Reports

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer

“…Cetuximab is the first FDA-approved anti-EGFR antibody therapeutic. It is an IgG1 chimeric (mouse–/human) monoclonal antibody that potentially inhibits EGF from binding to EGFR and disrupts EGFR dimerization, leading to inhibition of its cognate downstream signaling activation [ 40 , 41 ]. It also induces ADCC by NK cells and neutrophils [ 42 ].…”

MiR-335 promotes corneal neovascularization by Targeting EGFR

“…Epidermal Growth Factor Receptor (EGFR) is a transmembrane glycoprotein and exerts critical functions in regulating various cellular responses such as cell proliferation, differentiation and survival [ 23 , 24 ]. Abnormal expression of EGFR is associated with the development of CRNV.…”